Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CYTO -- Ignore unavailable to you. Want to Upgrade?

To: Darrel McPherson who wrote (7400)	11/14/1998 6:19:00 PM
From: Eric Freeman	Read Replies (1) \| Respond to of 8116

I posted the following on the Yahoo board, but will reiterate it here: I phoned the doctor, as he did post his number on the Yahoo board. He sounded very straight forward to me, and said that he stands by his information, "it came directly from a conversation with Angela Bidding". My take on this is as follows: Should one believe this is not true, and I have a bit of a hard time doing that, considering, he came on line, gave out his phone number, and further divulged his source. But, suppose his information is false, then why have we not heard the company refute same. Do you think they do not know about this? All of the conjecture, calling the doctor crazy etc., is a waste of time. Fact one: he has made a direct claim, fact two: we have not heard anything from the company saying it is not so, or from any other credible source. Draw your own conclusions. But putting down the docs claim without any facts is foolish. While believing his yet unsubstantiated claims may also not be wise. Is there any person from Cytogen who will speak to the substance of the rumour, or state that it is false? If so, then I will believe that the doctor speaks with fork tongue. Otherwise, the company does have a little credibility gap. Especially when taken in the context of the last few years, Cytogen has done nothing to enhance share holder value or communicate accurately there situations, would you not agree? I like the new management, BUT, results count, and when it comes to shareholders, the stock price will reflect all over time. We are all waiting Cytogen, lets get an answer. As for stock roll backs. No way it is good news. It happens when companies are failing, simple as that. I hold this stock, but am under no delusions about what a roll back means. Failure. And that is why you will find that in almost every case when you get a roll back it is followed by a LARGE decrease in your share value. It is this simple, and arguments to the contrary are rationalizations. What good companies with futures do is SPLIT the stock. If this company is working through problems and having any success, then the current share structure will reflect the increased valuation, and should remain in tact. Knowing how they do these things, I would suspect that if it is going to get rolled back, or just after, we might get one more (selling)opportunity but it will be short lived, since a roll back is a sign of failure. The problem here is that this company just NEVER seems to have its shareholders interests at heart. Eric

To: Darrel McPherson who wrote (7400)	11/24/1998 12:13:00 PM
From: Hoa Nguyen	Read Replies (2) \| Respond to of 8116

CYTOGEN Not to Implement Reverse Stock Split Tuesday, November 24, 1998 10:15 AM PRINCETON, N.J., Nov. 24 /PRNewswire/ -- Cytogen Corporation (Nasdaq: CYTO) announced today, in response to questions from investors, that the Company has been considering for some time the advisability of a reverse stock split, but has decided not to take such an action at this time. H. Joseph Reiser, Ph.D., CYTOGEN's President and Chief Executive Officer, commented, "We have carefully considered a reverse split for some time, and have concluded that it would not be in the best interest of our stockholders to take this step at the present time. Our recent progress in resolving CYTOGEN's current operating issues has been good, and we recognize that as we continue to strengthen our balance sheet and our operating results we may need to reconsider whether a reverse split is appropriate at a later date." CYTOGEN is a biopharmaceutical company engaged in the development, manufacture and commercialization of products for the targeted delivery of diagnostics and therapeutic substances directly to disease sites. CYTOGEN has demonstrated its ability to develop new technology from early discovery through clinical development, regulatory approval and commercial scale biologic manufacturing. Information in this press release which is not historical is forward looking and involves risks and uncertainties. Actual results may differ materially, for reasons discussed in the Company's filings with the Securities and Exchange Commission, including risks related to obtaining capital for the Company, ability to accomplish the Company's restructuring efforts, and commercial acceptance of the Company's products. SOURCE Cytogen Corporation CONTACT: Donald Crane of Cytogen Corporation, 609-520-3062